DEFA14A filed Jun 4, 2026 at 08:36 ET
Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No. 4 (2026 Equity Incentive Plan) at the June 10, 2026 annual meeting. The filing rebuts ISS's against recommendation by correcting the share count for the 5,060,185 shares canceled upon the 2015 Plan's expiration, reducing total potential basic dilution from ISS's 35.51% to 27.93%. The plan requests 7.2 million new shares with investor-friendly features (no evergreen, no repricing, clawback policy, 12-year modeled capacity).